Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00347802
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : June 1, 2007
Sponsor:
Information provided by:
Innovative Medical

Brief Summary:
To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Bimatoprost 0.03%, Travoprost 0.004% Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Naive to treatment or washed off any ocular hypotensive agents
    • Untreated IOP >19 mm Hg
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete study

Exclusion Criteria:

  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study
    • History of intraocular surgery within the last 3 months
    • Prior discontinuation of any of the study medications for reasons related to efficacy or safety

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00347802


Locations
Layout table for location information
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Layout table for investigator information
Principal Investigator: Robert Noecker, MD UPMC Eye Center

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00347802     History of Changes
Other Study ID Numbers: 5176
First Posted: July 4, 2006    Key Record Dates
Last Update Posted: June 1, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Ocular Hypertension
Eye Diseases
Bimatoprost
Travoprost
Antihypertensive Agents